{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:35:07Z","timestamp":1792409707592,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/00505"],"award-info":[{"award-number":["PI21\/00505"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011104","name":"Universitat Aut\u00f2noma de Barcelona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011104","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40263-023-01015-6","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T06:02:16Z","timestamp":1685512936000},"page":"489-497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Pharmacological Management of Borderline Personality Disorder and Common Comorbidities"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-9346","authenticated-orcid":false,"given":"Juan C.","family":"Pascual","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8077-3641","authenticated-orcid":false,"given":"Joaquim","family":"Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"1015_CR1","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edn. 2022. American Psychiatric Publishing. https:\/\/doi.org\/10.1176\/appi.books.9780890425787.","DOI":"10.1176\/appi.books.9780890425787"},{"issue":"10310","key":"1015_CR2","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/S0140-6736(21)00476-1","volume":"398","author":"M Bohus","year":"2021","unstructured":"Bohus M, Stoffers-Winterling J, Sharp C, et al. Borderline personality disorder. Lancet. 2021;398(10310):1528\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00476-1.","journal-title":"Lancet"},{"issue":"4","key":"1015_CR3","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1521\/pedi.2010.24.4.412","volume":"24","author":"TJ Trull","year":"2010","unstructured":"Trull TJ, Jahng S, Tomko RL, et al. Revised NESARC personality disorder diagnoses: gender, prevalence, and comorbidity with substance dependence disorders. J Pers Disord. 2010;24(4):412\u201326. https:\/\/doi.org\/10.1521\/pedi.2010.24.4.412.","journal-title":"J Pers Disord"},{"issue":"5","key":"1015_CR4","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1521\/pedi_2012_26_093","volume":"28","author":"RL Tomko","year":"2014","unstructured":"Tomko RL, Trull TJ, Wood PK, et al. Characteristics of borderline personality disorder in a community sample: comorbidity, treatment utilization, and general functioning. J Pers Disord. 2014;28(5):734\u201350. https:\/\/doi.org\/10.1521\/pedi_2012_26_093.","journal-title":"J Pers Disord"},{"issue":"4","key":"1015_CR5","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.psc.2018.07.009","volume":"41","author":"R Shah","year":"2018","unstructured":"Shah R, Zanarini MC. Comorbidity of borderline personality disorder: current status and future directions. Psychiatr Clin N Am. 2018;41(4):583\u201393. https:\/\/doi.org\/10.1016\/j.psc.2018.07.009.","journal-title":"Psychiatr Clin N Am"},{"issue":"5","key":"1015_CR6","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1521\/pedi_2016_30_269","volume":"31","author":"I Alvarez-Tom\u00e1s","year":"2017","unstructured":"Alvarez-Tom\u00e1s I, Soler J, Bados A, et al. Long-term course of borderline personality disorder: a prospective 10-year follow-up study. J Pers Disord. 2017;31(5):590\u2013605. https:\/\/doi.org\/10.1521\/pedi_2016_30_269.","journal-title":"J Pers Disord"},{"key":"1015_CR7","volume-title":"Cognitive-behavioral treatment of borderline personality disorder","author":"M Linehan","year":"1993","unstructured":"Linehan M. Cognitive-behavioral treatment of borderline personality disorder. New York: Guilford Press; 1993."},{"issue":"1","key":"1015_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40473-017-0103-z","volume":"4","author":"LW Choi-Kain","year":"2017","unstructured":"Choi-Kain LW, Finch EF, Masland SR, Jenkins JA, Unruh BT. What works in the treatment of borderline personality disorder. Curr Behav Neurosci Rep. 2017;4(1):21\u201330. https:\/\/doi.org\/10.1007\/s40473-017-0103-z.","journal-title":"Curr Behav Neurosci Rep"},{"key":"1015_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.copsyc.2017.12.006","volume":"21","author":"J Gunderson","year":"2018","unstructured":"Gunderson J, Masland S, Choi-Kain L. Good psychiatric management: a review. Curr Opin Psychol. 2018;21:127\u201331. https:\/\/doi.org\/10.1016\/j.copsyc.2017.12.006.","journal-title":"Curr Opin Psychol"},{"key":"1015_CR10","doi-asserted-by":"publisher","unstructured":"Storeb\u00f8 OJ, Stoffers-Winterling JM, V\u00f6llm BA, et al. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev. 2020;5(5):CD012955. https:\/\/doi.org\/10.1002\/14651858.CD012955.pub2.","DOI":"10.1002\/14651858.CD012955.pub2"},{"issue":"4","key":"1015_CR11","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/acps.13403","volume":"145","author":"J Soler","year":"2022","unstructured":"Soler J, Casellas-Pujol E, Fern\u00e1ndez-Felipe I, et al. \u201cSkills for pills\u201d: the dialectical-behavioural therapy skills training reduces polypharmacy in borderline personality disorder. Acta Psychiatr Scand. 2022;145(4):332\u201342. https:\/\/doi.org\/10.1111\/acps.13403.","journal-title":"Acta Psychiatr Scand"},{"key":"1015_CR12","doi-asserted-by":"publisher","unstructured":"Stoffers-Winterling JM, Storeb\u00f8 OJ, Pereira Ribeiro J, et al. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev. 2022;11(11):CD012956. https:\/\/doi.org\/10.1002\/14651858.CD012956.pub2.","DOI":"10.1002\/14651858.CD012956.pub2"},{"issue":"1","key":"1015_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/JCP.0000000000000232","volume":"35","author":"MC Zanarini","year":"2015","unstructured":"Zanarini MC, Frankenburg FR, Reich DB, et al. Rates of psychotropic medication use reported by borderline patients and axis II comparison subjects over 16 years of prospective follow-up. J Clin Psychopharmacol. 2015;35(1):63\u20137. https:\/\/doi.org\/10.1097\/JCP.0000000000000232.","journal-title":"J Clin Psychopharmacol."},{"issue":"5","key":"1015_CR14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/j.1600-0447.2011.01728.x","volume":"124","author":"MJ Crawford","year":"2011","unstructured":"Crawford MJ, Kakad S, Rendel C, et al. Medication prescribed to people with personality disorder: the influence of patient factors and treatment setting. Acta Psychiatr Scand. 2011;124(5):396\u2013402. https:\/\/doi.org\/10.1111\/j.1600-0447.2011.01728.x.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"1015_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/acps.12767","volume":"136","author":"A Mart\u00edn-Blanco","year":"2017","unstructured":"Mart\u00edn-Blanco A, Ancochea A, Soler J, et al. Changes over the last 15 years in the psychopharmacological management of persons with borderline personality disorder. Acta Psychiatr Scand. 2017;136(3):323\u201331. https:\/\/doi.org\/10.1111\/acps.12767.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"1015_CR16","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/13651501.2019.1576904","volume":"23","author":"F Riffer","year":"2019","unstructured":"Riffer F, Farkas M, Streibl L, et al. Psychopharmacological treatment of patients with borderline personality disorder: comparing data from routine clinical care with recommended guidelines. Int J Psychiatry Clin Pract. 2019;23(3):178\u201388. https:\/\/doi.org\/10.1080\/13651501.2019.1576904.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"4","key":"1015_CR17","doi-asserted-by":"publisher","first-page":"e512","DOI":"10.4088\/JCP.14m09228","volume":"76","author":"C Paton","year":"2015","unstructured":"Paton C, Crawford MJ, Bhatti SF, et al. The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services. J Clin Psychiatry. 2015;76(4):e512\u20138. https:\/\/doi.org\/10.4088\/JCP.14m09228.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"1015_CR18","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s40263-021-00852-7","volume":"35","author":"JC Pascual","year":"2021","unstructured":"Pascual JC, Mart\u00edn-Blanco A, Soler J. Twenty-year trends in psychopharmacology treatment of outpatients with borderline personality disorder: a cross-sectional naturalistic study in Spain. CNS Drugs. 2021;35(9):1023\u201332. https:\/\/doi.org\/10.1007\/s40263-021-00852-7.","journal-title":"CNS Drugs"},{"key":"1015_CR19","unstructured":"National Collaborating Centre for Mental Health (UK). Borderline personality disorder: treatment and management. British Psychological Society (UK); 2009. PMID: 21796831."},{"issue":"6","key":"1015_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/YIC.0b013e32833e23ed","volume":"25","author":"JC Pascual","year":"2010","unstructured":"Pascual JC, Mart\u00edn-Blanco A, Soler J, et al. A naturalistic study of changes in pharmacological prescription for borderline personality disorder in clinical practice: from APA to NICE guidelines. Int Clin Psychopharmacol. 2010;25(6):349\u201355. https:\/\/doi.org\/10.1097\/YIC.0b013e32833e23ed.","journal-title":"Int Clin Psychopharmacol"},{"issue":"8","key":"1015_CR21","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.4088\/jcp.v65n0804","volume":"65","author":"JG Gunderson","year":"2004","unstructured":"Gunderson JG, Morey LC, Stout RL, et al. Major depressive disorder and borderline personality disorder revisited: longitudinal interactions. J Clin Psychiatry. 2004;65(8):1049\u201356. https:\/\/doi.org\/10.4088\/jcp.v65n0804.","journal-title":"J Clin Psychiatry"},{"key":"1015_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0165-0327(95)00091-7","volume":"37","author":"E Corruble","year":"1996","unstructured":"Corruble E, Ginestet D, Guelfi J. Comorbidity of personality disorders and unipolar major depression: a review. J Affect Disord. 1996;37:157\u201370. https:\/\/doi.org\/10.1016\/0165-0327(95)00091-7.","journal-title":"J Affect Disord"},{"issue":"6","key":"1015_CR23","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/1039856219878643","volume":"27","author":"S Rao","year":"2019","unstructured":"Rao S, Broadbear J. Borderline personality disorder and depressive disorder. Australas Psychiatry. 2019;27(6):573\u20137. https:\/\/doi.org\/10.1177\/1039856219878643.","journal-title":"Australas Psychiatry"},{"issue":"3","key":"1015_CR24","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1176\/appi.ajp.2010.10050695","volume":"168","author":"AE Skodol","year":"2011","unstructured":"Skodol AE, Grilo CM, Keyes KM, et al. Relationship of personality disorders to the course of major depressive disorder in a nationally representative sample. Am J Psychiatry. 2011;168(3):257\u201364. https:\/\/doi.org\/10.1176\/appi.ajp.2010.10050695.","journal-title":"Am J Psychiatry"},{"issue":"11","key":"1015_CR25","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1176\/appi.ajp.161.11.2108","volume":"161","author":"MC Zanarini","year":"2004","unstructured":"Zanarini MC, Frankenburg FR, Hennen J, et al. Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission. Am J Psychiatry. 2004;161(11):2108\u201314. https:\/\/doi.org\/10.1176\/appi.ajp.161.11.2108.","journal-title":"Am J Psychiatry"},{"key":"1015_CR26","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12888-019-2230-4","volume":"19","author":"M Pl\u00f6derl","year":"2019","unstructured":"Pl\u00f6derl M, Hengartner MP. Guidelines for the pharmacological acute treatment of major depression: conflicts with current evidence as demonstrated with the German S3-guidelines. BMC Psychiatry. 2019;19:265. https:\/\/doi.org\/10.1186\/s12888-019-2230-4.","journal-title":"BMC Psychiatry"},{"key":"1015_CR27","doi-asserted-by":"publisher","unstructured":"Bauer M, Severus E, K\u00f6hler S, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015. World J Biol Psychiatry. 2015;16(2):76\u201395. https:\/\/doi.org\/10.3109\/15622975.2014.1001786.","DOI":"10.3109\/15622975.2014.1001786"},{"issue":"9","key":"1015_CR28","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1177\/0706743716659417","volume":"61","author":"SH Kennedy","year":"2016","unstructured":"Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological treatments. Can J Psychiatry. 2016;61(9):540\u201360. https:\/\/doi.org\/10.1177\/0706743716659417.","journal-title":"Can J Psychiatry"},{"issue":"9","key":"1015_CR29","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1177\/0706743716659418","volume":"61","author":"SV Parikh","year":"2016","unstructured":"Parikh SV, Quilty LC, Ravitz P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 2. Psychological treatments. Can J Psychiatry. 2016;61(9):524\u201339. https:\/\/doi.org\/10.1177\/0706743716659418.","journal-title":"Can J Psychiatry"},{"key":"1015_CR30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jad.2020.11.111","volume":"281","author":"A Ceresa","year":"2021","unstructured":"Ceresa A, Esposito CM, Buoli M. How does borderline personality disorder affect management and treatment response of patients with major depressive disorder? A comprehensive review. J Affect Disord. 2021;281:581\u20139. https:\/\/doi.org\/10.1016\/j.jad.2020.11.111.","journal-title":"J Affect Disord."},{"issue":"8","key":"1015_CR31","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1176\/appi.ajp.2018.17091006","volume":"175","author":"MJ Crawford","year":"2018","unstructured":"Crawford MJ, Sanatinia R, Barrett B, et al. The clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder: a randomized placebo-controlled trial. Am J Psychiatry. 2018;175(8):756\u201364. https:\/\/doi.org\/10.1176\/appi.ajp.2018.17091006.","journal-title":"Am J Psychiatry"},{"key":"1015_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40479-017-0064-6","volume":"4","author":"M Elices","year":"2017","unstructured":"Elices M, Soler J, Feliu-Soler A, et al. Combining emotion regulation and mindfulness skills for preventing depression relapse: a randomized-controlled study. Borderline Personal Disord Emot Dysregul. 2017;4:13. https:\/\/doi.org\/10.1186\/s40479-017-0064-6.","journal-title":"Borderline Personal Disord Emot Dysregul."},{"issue":"4","key":"1015_CR33","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00406-021-01324-1","volume":"272","author":"B Bandelow","year":"2022","unstructured":"Bandelow B, Werner AM, Kopp I, et al. The German guidelines for the treatment of anxiety disorders: first revision. Eur Arch Psychiatry Clin Neurosci. 2022;272(4):571\u201382. https:\/\/doi.org\/10.1007\/s00406-021-01324-1.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1015_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.brat.2014.01.008","volume":"55","author":"MS Harned","year":"2014","unstructured":"Harned MS, Korslund KE, Linehan MM. A pilot randomized controlled trial of dialectical behavior therapy with and without the dialectical behavior therapy prolonged exposure protocol for suicidal and self-injuring women with borderline personality disorder and PTSD. Behav Res Ther. 2014;55:7\u201317. https:\/\/doi.org\/10.1016\/j.brat.2014.01.008.","journal-title":"Behav Res Ther"},{"issue":"6","key":"1015_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40479-019-0106-3","volume":"21","author":"S Simonsen","year":"2019","unstructured":"Simonsen S, Bateman A, Bohus M, et al. European guidelines for personality disorders: past, present and future. Borderline Person Disord Emot Dysregul. 2019;21(6):9. https:\/\/doi.org\/10.1186\/s40479-019-0106-3.","journal-title":"Borderline Person Disord Emot Dysregul."},{"key":"1015_CR36","doi-asserted-by":"publisher","unstructured":"Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry 2014;14(Suppl 1):S1. https:\/\/doi.org\/10.1186\/1471-244X-14-S1-S1.","DOI":"10.1186\/1471-244X-14-S1-S1"},{"issue":"9","key":"1015_CR37","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1176\/ps.2007.58.9.1199","volume":"58","author":"JC Pascual","year":"2007","unstructured":"Pascual JC, C\u00f3rcoles D, Casta\u00f1o J, et al. Hospitalization and pharmacotherapy for borderline personality disorder in a psychiatric emergency service. Psychiatr Serv. 2007;58(9):1199\u2013204. https:\/\/doi.org\/10.1176\/ps.2007.58.9.1199.","journal-title":"Psychiatr Serv"},{"issue":"1","key":"1015_CR38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/10640260590893593","volume":"13","author":"RA Sansone","year":"2005","unstructured":"Sansone RA, Levitt JL, Sansone LA. The prevalence of personality disorders among those with eating disorders. Eat Disord. 2005;13(1):7\u201321. https:\/\/doi.org\/10.1080\/10640260590893593.","journal-title":"Eat Disord"},{"issue":"2","key":"1015_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3390\/jcm8020153","volume":"8","author":"G Resmark","year":"2019","unstructured":"Resmark G, Herpertz S, Herpertz-Dahlmann B, Zeeck A. Treatment of anorexia nervosa-new evidence-based guidelines. J Clin Med. 2019;8(2):153. https:\/\/doi.org\/10.3390\/jcm8020153.","journal-title":"J Clin Med"},{"issue":"6","key":"1015_CR40","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/YCO.0000000000000360","volume":"30","author":"A Hilbert","year":"2017","unstructured":"Hilbert A, Hoek HW, Schmidt R. Evidence-based clinical guidelines for eating disorders: international comparison. Curr Opin Psychiatry. 2017;30(6):423\u201337. https:\/\/doi.org\/10.1097\/YCO.0000000000000360.","journal-title":"Curr Opin Psychiatry"},{"issue":"6","key":"1015_CR41","first-page":"226","volume":"46","author":"I Carmona","year":"2018","unstructured":"Carmona I, Farr\u00e9s C, Pascual JC, Elices M, et al. Factors predicting early dropout from dialectical behaviour therapy in individuals with borderline personality disorder. Actas Esp Psiquiatr. 2018;46(6):226\u201333 (PMID: 30552812).","journal-title":"Actas Esp Psiquiatr"},{"issue":"16","key":"1015_CR42","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3238\/arztebl.2014.0280","volume":"111","author":"T Kienast","year":"2014","unstructured":"Kienast T, Stoffers J, Bermpohl F, Lieb K. Borderline personality disorder and comorbid addiction. Dtsch Arztebl Int. 2014;111(16):280\u20136. https:\/\/doi.org\/10.3238\/arztebl.2014.0280.","journal-title":"Dtsch Arztebl Int"},{"issue":"2","key":"1015_CR43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1151\/ascp084239","volume":"4","author":"LA Dimeff","year":"2008","unstructured":"Dimeff LA, Linehan MM. Dialectical behavior therapy for substance abusers. Addict Sci Clin Pract. 2008;4(2):39\u201347. https:\/\/doi.org\/10.1151\/ascp084239.","journal-title":"Addict Sci Clin Pract"},{"key":"1015_CR44","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/NMD.0b013e3181d6172d","volume":"198","author":"RJ Gregory","year":"2010","unstructured":"Gregory RJ, DeLucia-Deranja E, Mogle JA. Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occurring with alcohol use disorders: a 30-month follow-up. J Nerv Ment Dis. 2010;198:292\u20138. https:\/\/doi.org\/10.1097\/NMD.0b013e3181d6172d.","journal-title":"J Nerv Ment Dis"},{"issue":"6","key":"1015_CR45","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/s0306-4603(98)00067-7","volume":"23","author":"SA Ball","year":"1998","unstructured":"Ball SA. Manualized treatment for substance abusers with personality disorders: dual focus schema therapy. Addict Behav. 1998;23(6):883\u201391. https:\/\/doi.org\/10.1016\/s0306-4603(98)00067-7.","journal-title":"Addict Behav"},{"issue":"1","key":"1015_CR46","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1176\/appi.ajp.2017.1750101","volume":"175","author":"VI Reus","year":"2018","unstructured":"Reus VI, Fochtmann LJ, Bukstein O, et al. The american psychiatric association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry. 2018;175(1):86\u201390. https:\/\/doi.org\/10.1176\/appi.ajp.2017.1750101.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"1015_CR47","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/s2215-0366(18)30135-4","volume":"5","author":"MC Mithoefer","year":"2018","unstructured":"Mithoefer MC, Mithoefer AT, Feduccia AA, et al. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorderin military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry. 2018;5(6):486\u201397. https:\/\/doi.org\/10.1016\/s2215-0366(18)30135-4.","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"1015_CR48","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00213-018-5085-3","volume":"236","author":"E Dom\u00ednguez-Clav\u00e9","year":"2019","unstructured":"Dom\u00ednguez-Clav\u00e9 E, Soler J, Pascual JC, et al. Ayahuasca improves emotion dysregulation in a community sample and in individuals with borderline-like traits. Psychopharmacology. 2019;236(2):573\u201380. https:\/\/doi.org\/10.1007\/s00213-018-5085-3.","journal-title":"Psychopharmacology"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01015-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-023-01015-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01015-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T05:21:01Z","timestamp":1686979261000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-023-01015-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1015"],"URL":"https:\/\/doi.org\/10.1007\/s40263-023-01015-6","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,31]]},"assertion":[{"value":"15 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by the Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental (CIBERSAM) and by a grant from Instituto de Salud Carlos III (PI21\/00505) and co-financed by the European Regional Development Fund (ERDF).\u00a0Open Access Funding provided by Universitat Autonoma de Barcelona.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Juan C. Pascual, Laia Arias, and Joaquim Soler declare they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study adhered to the principles outlined in the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All three authors contributed equally to designing and writing this manuscript and approved the final version for submission and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}